Serious Bone Problems From Multiple Myeloma

Prevent Serious Bone Problems Before They Occur1

Bone lesions from multiple myeloma can cause serious bone problems2,3

Normally, your body is continually breaking down and rebuilding bone. This helps keep your bones strong. In a person with bone lesions from multiple myeloma, the breakdown and rebuilding of your bones can become unbalanced.3-5

Bone lesions can weaken the bone and can lead to serious bone problems.2,3

Serious bone problems are defined as6:

Fracture to the bone

Broken bones (fractures)

Radiation treatment to the bone

A need for radiation treatments to the bone

Surgery to prevent or repair broken bones

A need for surgery to prevent or repair broken bones

Spinal pressure

Pressure on the spinal cord (spinal cord compression)

People with multiple myeloma are at risk for serious bone problems7,8

  • Multiple Myeloma Bone Problems

    Of people with MULTIPLE MYELOMA,

    about 6 out of 10

    will develop a fracture8

If you have multiple myeloma,

you can prevent serious bone problems6

As a patient or caregiver, it's important for you to be informed and proactive about the potential impact of weakened bones. What you learn today can make a difference in the future.

Learn how XGEVA® can prevent serious bone problems in:

Important Safety Information


Do not take XGEVA® if you have low blood calcium (hypocalcemia). Your low blood calcium must be treated before you receive XGEVA®. XGEVA® can significantly lower the calcium levels in your blood and some deaths have been reported. Take calcium and vitamin D as your doctor tells you to. Tell your doctor right away if you experience spasms, twitches, cramps, or stiffness in your muscles or numbness or tingling in your fingers, toes, or around your mouth.

Do not take XGEVA® if you are allergic to denosumab or any of the ingredients of XGEVA®. Serious allergic reactions have happened in people who take XGEVA®. Call your doctor or go to your nearest emergency room right away if you have any symptoms of a serious allergic reaction, including low blood pressure (hypotension); trouble breathing; throat tightness; swelling of the face, lips, or tongue, rash; itching; or hives.

What is the most important information you should know about XGEVA®?

Do not take XGEVA® if you take Prolia. XGEVA® contains the same medicine as Prolia® (denosumab).

Severe jaw bone problems (osteonecrosis)

Unusual thigh bone fracture

Risk of high calcium levels in patients who are still growing

Increased risk of broken bones in the spine after discontinuing XGEVA®

Possible harm to your unborn baby

Tell your doctor if you:

While taking XGEVA®, you should:

What are the possible side effects of XGEVA®?

These are not all the possible side effects of XGEVA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Full Prescribing Information.

Indication

XGEVA® is a prescription medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.

References:
  1. Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018:36(8):812-820.
  2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
  3. Heusschen R, Muller J, Duray E, et al. Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leuk Lymphoma. 2018;59(1):14-28.
  4. American Cancer Society. Understanding advanced cancer, metastatic cancer, and bone metastasis website. https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/what-is.html. Revised December 15, 2016. Accessed April 30, 2018.
  5. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 2008;34(1):92-101.
  6. XGEVA® (denosumab) prescribing information, Amgen.
  7. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3):435-441.
  8. Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-493.